Treatments for Severe Inflammatory Diseases

Azome Therapeutics is focused on developing innovative treatments for severe inflammatory diseases by targeting the NLRP3 inflammasome, a critical pathway involved in various inflammatory conditions. Their drug discovery platform aims to create selective antagonists that can effectively inhibit the aberrant activation of this inflammasome, which is implicated in diseases such as Acute Respiratory Distress Syndrome (ARDS), Bronchopulmonary Dysplasia (BPD), and systemic sepsis. The lead candidate, AZM-152, is a RHAMM-derived antagonist that disrupts a key priming signal necessary for NLRP3 activation, thereby potentially offering a therapeutic solution for conditions that currently lack effective treatments.

The underlying technology of Azome Therapeutics revolves around the role of hyaluronan (HA) and its receptor, RHAMM, in the inflammatory response. In severe inflammatory diseases, elevated levels of HA and the expression of RHAMM contribute to the activation of the NLRP3 inflammasome. By developing AZM-152, which specifically targets the HA binding site on RHAMM, Azome aims to prevent NLRP3 activation and mitigate inflammation. Their research has shown promising results in preclinical models, demonstrating the potential of AZM-152 to address significant unmet medical needs in the treatment of severe pulmonary diseases.

United States

Azome Therapeutics is an early-stage drug discovery company focused on developing selective antagonists of the NLRP3 inflammasome, an inflammatory pathway critical to the development of a wide variety of diseases.  

Our lead candidate, AZM-152, is a RHAMM-derived antagonist that blocks a key upstream priming signal involved in the aberrant activation of the NLRP3 inflammatory cascade.

Azome Therapeutics

Company Details